Study of molecular mechanisms of anti-tuberculosis activity of 5,6-dimethyl-2-(alkylthio)-3-phenylthieno[2,3-d]pyrimidine-4(3H)-one derivatives

Abstract

Among the population of our planet, a significant number of people are carriers of the causative agent of tuberculosis. The causative agent of this disease, M. tuberculosis, can cause disease in any part of the body (extrapulmonary tuberculosis), but the main and most problematic form of the disease is pulmonary tuberculosis, which is the most common of all. The treatment regimen for tuberculosis includes a combination of four drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol, administered for at least 6 months. But in cases of persistent tuberculosis, this scheme may not be effective. Therefore, innovative approaches to the creation of anti-tuberculosis drugs are relevant.